ProteinLogic Ltd. is a British private company located in Cambridge. The firm develops technology platform for diagnosis of tuberculosis.

Caprion Proteomics, Inc. provides proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. It specializes in proteomics, biomarkers, discovery, validation, services, immune monitoring, flow cytometry and elispot areas. The company was founded by Neil Cashman and Martin LeBlanc in 2000 and is headquartered in Montreal, Canada.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Red Flag Diagnostics GmbH operates as a holding company, which engages in the development and sale of tests for the diagnosis of tuberculosis. The company was founded on December 14, 2009 and is headquartered in Saarbruecken, Germany.

TB Healthcare is a provider of tuberculosis prevention, diagnosis, and treatment services. They provide comprehensive tuberculosis solutions, including clinical in vitro diagnostic reagents, bacterial ultrasonic dispersive counters, vacuum pumps, and proteome products.

Infectious Disease Research Institute operates as a innovative science to research and development company. It offers pipeline, adjuvants, vaccines, diagnostics and drugs products. The firm also provides manufacturing, analytical methods, stability studies, process and contact services. The company was founded by Steven G. Reed in 1993 and is headquartered in Seattle, WA.

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

The Korea Atomic Energy Research Institute (KAERI) in Daejeon, South Korea was established in 1959 as the sole professional research-oriented institute for nuclear power in South Korea, and has rapidly built a reputation for research and development in various fields. In 1995 KAERI designed and constructed the nation's first multipurpose research reactor, HANARO based on the Canadian MAPLE design. KAERI is dedicated to finding a wide range of uses for atomic energy. As examples, KAERI developed the world's first radiopharmaceutical "Milican injection" for treating liver cancer.

Japan BCG Laboratory KK engages in vaccine development. It specializes in the research, development, and marketing of Bacillus-Calmette Gu��rin vaccine. The firm vaccine consists of live bacteria that are used for the treatment of tuberculosis and is the sole supplier in Japan. It offers Freeze-Dried BCG Vaccine for Intradermal Use, Freeze-Dried BCG Vaccine for Percutaneous Use, Freeze-Dried Tuberculin, Purified Protein Derivative(PPD), and Immunobladder�� Intravesical. The company was founded in 1952 and is headquartered in Tokyo, Japan.

Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area of Immunology and T-cell diagnostics. Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.

Shanghai Public Health Clinical Center is a Chinese company located in Shanghai and ultimately controlled by the Government of China that operates hospital and provides education and training for disease control and prevention.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Beijing Wantai is a manufacturer of infectious disease diagnostics. It operates domestic and international diagnostic test businesses in the fields of human infectious diseases and screening of blood donors. Its customers are blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. Innovax is a separate division of Wantai that focuses on the development and commercialization of recombinant vaccines. Innovax's flagship product Hecolin, is the world's first launched Hepatitis E vaccine. Its production facilities are GMP, ISO9001 and ISO13485 certified. Founded in 1991, Beijing Wantai is headquartered in Beijing, China.